PUBLISHER: IMARC | PRODUCT CODE: 1519432
PUBLISHER: IMARC | PRODUCT CODE: 1519432
The global pediatric interventional cardiology market size reached US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
Pediatric interventional cardiology is a subset of cardiology that involves the use of specific catheter-based techniques to treat heart disorders in infants, children, and adolescents upto 18 years of age. They include balloon angioplasty, coil occlusion, stent implantation, and aortic valve stenosis. As compared to conventional cardiological treatments, pediatric interventional cardiology is more minimally invasive, thus reducing post-surgerycomplications. Consequently, they are extensively employed for performing angioplasty, valvuloplasty, coronary thrombectomy, and congenital heart defect correction procedures across clinical testing laboratories, hospitals, cardiac centers, and research institutes.
Theincreasing instances of various congenital cardiac diseases in children, such as atrial septal defect (ASD), atrioventricular canal defect, patent ductus arteriosus (PDA), and ventricular septal defect (VSD) represent one of the key factors driving the pediatric interventional cardiology market growth. The introduction of novel and more efficient pediatric interventional cardiology devices, including catheters, bio-absorbable stents, guidewires, balloons, stents, vascular closure devices, atherectomy devices is acting as another major growth-inducing factor.In line with this, the shifting inclination of patients toward non-invasive medical treatment procedures, along with the rising awareness regarding the associated benefits, such as lower risk of infection, shorter postoperative recovery times, and avoidance of large scars is also driving the market growth. Other factors, including rising healthcare expenditure and the numerous initiatives being undertaken by governments of various nations to speed-up regulatory procedures, are creating a positive outlook for the market. The market is also driven by extensive research and development (R&D) activities, increasing consumer healthcare expenditure and investments by governments and non-government organizations (NGOs) for strengthening the existing healthcare infrastructure, and significant technological advancements in the field of cardiology.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pediatric interventional cardiology market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on device type, procedure and end use.
Closure Devices
Transcatheter Heart Valves
Atherectomy Devices
Catheters
Balloons
Stents
Others
Catheter-Based Valve Implantation
Congenital Heart Defect Correction
Angioplasty
Coronary Thrombectomy
Others
Clinical Testing Laboratories
Hospitals
Cardiac Centers
Pediatric Clinics
Research Institutions
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biotronik SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Edwards Lifesciences Corporation, General Electric Company, Koninklijke Philips N.V., Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, NuMED Inc., Siemens Healthineers AG, Terumo Corporation and W. L. Gore & Associates Inc.